EXCLUSIVE: New Phytocannabinoid Drug Discovery Platform To Accelerate Creation Of Plant-Based Medicines Launches

Dr. Pierre Debs, Ph.D., the founder of Chain Pharmaceuticals GmbH is launching a new phytocannabinoid drug discovery platform that will leverage machine learning and real-world medical data in the development of clinically proven plant-based medicines for market authorization. Debs has over twenty years of experience in stem cell research and opened the European market, in particular Germany, for import and distribution licenses for Canadian cannabis flowers.

The idea behind Chain Pharmaceuticals was to create a unique platform and procedure to help accelerate the process of design and execution of clinical trials for cannabis-based molecules, without waiting 10 years and at enormous cost. It achieves this by bringing together pharmaceutical, medical, marijuana, and digital experts.

“Our core energies are focused on bringing plant-based pharmaceutical products to the market in an expedited time frame with higher efficiencies, less up-front costs, longer-term equitable returns, and in a sustainable manner,” Debs, founder and chief executive officer of Chain Pharmaceuticals GmbH stated. “Clinically proven market authorized medications are sine qua non for long-term demands of all stake-holders throughout European healthcare systems.”

Chain Pharmaceuticals will release a series of unique and differentiated solventless extract-based products for the current regulations throughout the European Union in the coming year. Chain extracts are designed with a purpose and play an integral role in tracking efficacy and patient usage outcomes.

Five Core Principles 

The Chain Pharmaceuticals ecosystem is driven by five major trends shaping the future of medicine: 

1. The power of machine learning, artificial intelligence, and in silico modeling to expedite and reduce the cost of drug discovery;
2. The ability of blockchain to facilitate data-gathering and patient engagement;
3. Harnessing the power of the real world, evidence-based data in the design of health care therapies;
4. Increased desire for and expanded use of plant-based pharmaceuticals;
5. The advances and momentum in personalized medicine as a leading paradigm in health care;

“Decentralized and personalized phytocannabinoid-based healthcare solutions require GDPR compliant, transparent, rapid, targeted data acquisition and analysis,” co-founder and CIO Dr. Pavel Kubu, MD said in a statement. “Our HealChain App is the synergistic meeting point for data from real-world usage, continually updated cannabis patient usage, and a broad palate of machine learning-driven resources specifically designed for each subscriber.”

Debs added, “We started our discovery pipeline last year, targeting four indications and one bio-medical product, and have progressed through the mid-stages of in silico discovery – once the real-world data is infused, we anticipate several exciting outcomes.” 

HealChain, which will launch in the coming months, will serve as one of the feeds for the machine learning systems by incentivizing medical cannabis patients to share data for the design of clinical trials with patients owning and licensing their anonymized data. The HealChain app is a joint venture between Chain Pharmaceuticals and Innoplexus, based on the latter’s Curia and Neuria apps.

Photo: Courtesy of Chain Pharmaceuticals